AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 27 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have developed a novel assay for testing antimicrobial peptide agents.
"Peptides that exert antimicrobial activity in artificial media may lack activity within blood or other complex biological matrices," explained Michael R. Yeaman and colleagues working at the University of California at Los Angeles.
Yeaman and coauthors developed an ex vivo biomatrix assay that enables analysis of peptide therapy candidates in a relevant environment.
The researchers designed a complex fluid matrix made up of whole blood, plasma, and serum. This biomatrix was used to evaluate the antimicrobial properties of a pair of potential peptide agents, dubbed RP-1 and RP-11, according to the report.
The addition of either peptide candidate into the biomatrix significantly reduced Escherichia coli levels, study data showed. In fact, both RP-1 and RP-11 had more pronounced effects in the biomatrix model than in simple culture media.